1952 Founding of CCPC engages in the manufacture and sale of pharmaceuticals, and related pharmaceutical import/export services.  1953 Signs contract with Sankyo Co., Ltd. of Japan for the production and marketing of Sankyo products. 1959  MOEA approves technological partnership with the American firm E.R. Squibb. 1960 A new R&D building established at the Shulin plant in order to boost quality control and medication R&D.  1960 Obtains general agent rights for Sankyo pharmaceuticals and pesticides in ROC territory.
	1962  Awarded first place, pharmaceutical division, in the MOEA's Quality Awards, for most improved private factory. 1962  First company in Taiwan authorized by the MOEA to go public; stock publicly listed. 1963 Obtains ROC general agent rights for the pharmaceutical products of Morishita Pharmaceutical Co., Ltd. 1964  Awarded inspection approval by the US FDA, making the company the first general pharmaceutical manufacturer in Taiwan to receive acknowledgement from the US government.  1965 Collaborates with the Dutch pharmaceutical firm Organon B.V. to produce that company's Durabolin and Orgabolin products. 1966 Signs an ROC general agent contract for the diagnostic pharmaceuticals of the Ames Company (United States), and began sales. 1968 Signs a general agent contract with the Siam Pharmaceutical Co., Ltd. for the marketing and sale of the company's products in Thailand. 1969 Founder Wang Min-ning visits Thailand to inspect agent sales and observe the Southeast Asian pharmaceutical market.
	1972 Embarks on diversification by introducing Bailing Alkaline Toothpaste, which is popular with consumers. 1972  Collaborates with the Italian firm Lepetit to manufacture that company's patented pharmaceutical product RIF Capsules in Taiwan. 1974  Signs a contract with Japan's Hana Seisakusho Co., Ltd. making China Chemical Pharmaceutical Taiwan general agent for that company's pharmaceutical machinery.  1975 The MOEA approves technology collaboration between this company and Morishita Pharmaceutical Co., Ltd. in the manufacture of the injectable drug Moriamin for sale in Taiwan. 1976 Obtains ROC general agent rights for the infant formula Bebelac Humanized No. 1 by the Dutch firm Lijempf B.V.  1976  Collaborates with the Belgian firm Janssen Pharmaceutical N.V. to produce animal drugs in Taiwan. Collaborates with the Belgian firm Janssen Pharmaceutical N.V. to produce animal drugs in Taiwan. 1976 Collaborates with the West German firm Kali Chemie to jointly produce pharmaceuticals in Taiwan. 1976  Builds a new plant and research building complying with WHO's Good Manufacturing Practice (GMP) standards.  1977 Signs a contract with the major US pharmaceutical firm Syntex Laboratories for the production and sale of that company's patented preparation Naposin in Taiwan.  1977  Signs a contract with the Japanese firm Kureha Chemical Industry Co., Ltd. for ROC general agent rights to the anti-cancer drug Krestin. 1977 Authorizes Namchow Chemical Industrial Co., Ltd. to produce this company's Green Herbal Soap. 1978  First pharmaceutical manufacturer in Taiwan's to implement a GMP system; company opens a new factory meeting GMP standards.  1979  Signs a contract with IBM for the installation of computers, allowing the company to implement modern corporate management.  1979  Signs a contract with the Italian firm Farmitalia CarloErba for the joint production and sale of the diabetes drug Glidiab Tablets. 1979 Signs a technology collaboration contract with the US firm Smith Kline & French Overseas Co. for the production and sale of that company's patented Tagamet Tablets in Taiwan.  1980 Signs a contract with the Swedish pharmaceutical firm Asta making China Chemical Pharmaceutical ROC general agent for that company's anti-hypertension drug Betaloc Tablets.
	1985 Signs a contract with the Japanese firm Koyaki Pharmaceutical Ind. Co., Ltd. for Taiwan sales agent rights to that company's arterial embolism drugs and Promostan.  1986 President Wang Min-ning signs a general agent contract with the president of Sankyo in Tokyo on March 19. 1989 Establishment of the Wang Ming-Ning Foundation in order to sponsor medical research. 1997 Completion of Hsinfeng plant—Taiwan's first pharmaceutical factory meeting cGMP requirements. 1998 Receives National Gold Award for Medical Quality.
	2000 China Chemical signs a contract with the US firm SynZyme Technologies LLC allowing the joint development of that company's proprietary platform technology, which has the potential to eliminate harmful free radicals. CCPC and SCCPC plan to use this technology in new drug development and clinical trials. 2000 Recipient of the National Biotechnology and Health Care Quality Award.  2001 Receives the Gold Medal for Manufacturing Technology in the 1st Pharmaceutical Technology Research and Development Awards. 2003 China Chemical's Hsinfeng and Taichung plants pass DOH audit, and become the first factories in Taiwan to be certified as whole-plant, all-dosage form stage 3 cGMP general pharmaceutical plants.
	2005 Purchases Sankyo's Tainan plant, which becomes China Chemical's second Tainan plant.  2008 Tainan no. 1 plant passes ISO22000：2005  2009 The ground-breaking ceremoney of CCPC's Tainan Cephalosporin Plant III. 2010 Taichung plant acquired Department of Health PIC/S Certification. 2010 Hsinfeng Plant acquired Department of Health PIC/S Certification. 2011 Tainan plant II acquired Department of Health PIC/S Certification. 2011 Tainan plant III acquired Department of Health PIC/S Certification. 2012 The ground-breaking ceremony of Tainan plant I for animal injections, solutions, and ointments meets the cGMP requirements. 2013 Tainan plant II  acquired TFDA PIC/S Certification.